Publications by authors named "Robert S Croop"
Article Synopsis
- - Zavegepant is a new nasal spray medication approved in the U.S. for acute migraine treatment in adults, available in a 10 mg dose, effective for migraines with or without aura.
- - The cardiovascular safety of zavegepant was examined through two studies (single and multiple ascending doses) involving a total of 144 healthy participants, focusing on its effects on ECG parameters like heart rate and QT interval.
- - Results indicated that zavegepant does not significantly affect ECG parameters or cause meaningful QT interval prolongation, even at doses up to four times the recommended amount.
A single-center, phase I, partially double-blind (double-blind regarding doses of rimegepant and placebo, and open label with respect to moxifloxacin), randomized, 12-sequence, four-period crossover study of therapeutic (75 mg) and supratherapeutic (300 mg) doses of rimegepant with placebo and moxifloxacin (400 mg) controls was designed to evaluate drug effect on the Fridericia corrected QT (QTcF) interval in healthy fasted adults. A total of 38 participants were randomized and dosed in the study. Electrocardiogram (ECG) data were available from 37 participants in the rimegepant 75-mg group, 38 participants in the rimegepant 300-mg group, and 36 participants in the moxifloxacin and placebo groups.
View Article and Find Full Text PDFObjective: To assess the effect of single and multiple doses of rimegepant 75 mg dose on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol (EE)/norgestimate (NGM) in healthy females of childbearing potential or non-menopausal females with tubal ligation.
Background: Females of childbearing age experience the highest prevalence of migraine and frequently inquire about the concomitant use of anti-migraine medications and contraceptives. Rimegepant, a calcitonin gene-related peptide receptor antagonist, demonstrated efficacy and safety for treating an acute migraine attack and preventing migraine.